US equities |
NVDA $240.73 ▲+0.76% SPCX $173.62 ▲+1.48% MU $1,065.66 ▲+0.16% MRVL $286.70 ▲+5.70% AMD $655.86 ▲+3.82% SNDK $1,673.00 ▼-1.83% AVGO $378.25 ▲+4.34% INTC $113.14 ▼-2.63%
FinancialContent

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

54.66 -0.95 (-1.72%)
Delayed Quote Updated: 12:30 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Eton Pharmaceuticals (NASDAQ:ETON): High Growth Momentum Meets a Breakout Setup ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript ↗
Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth. 
Via The Motley Fool
Topics Earnings
Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Posts Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Why Eton Pharmaceuticals Is Top of the Class Today ↗
Eton's cure for an expensive valuation: a 99% sales growth rate. 
Via The Motley Fool
Keep an eye on the top gainers and losers in Friday's session. ↗
Via Chartmill
Friday's session: gap up and gap down stocks ↗
Via Chartmill
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Q2 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter revenue nearly doubled from a year earlier, driven by the relaunch of HEMANGEOL and growth across its pediatric endocrinology and rare-disease... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript ↗
Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide... 
Via Benzinga
Topics Earnings
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q1 2026 Earnings Call Transcript ↗
Eton (ETON) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
Eton Pharmaceuticals (NASDAQ:ETON) raised its 2026 revenue outlook after reporting record first-quarter product sales and highlighting early progress from two recent product launches, DESMODA and... 
Via MarketBeat
Topics Earnings
News headline image
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
-- Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease -- 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces CFO Succession Plan
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Earnings Call Transcript ↗
Eton Pharma (ETON) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9 Next >